8-K: Gyre Therapeutics Completes Cullgen Acquisition

Gyre Therapeutics has finalized its acquisition of Cullgen Inc. in an all-stock deal valued at approximately $300 million, creating a combined biopharmaceutical entity with U.S. and China operations.

Summary

• Gyre Therapeutics, Inc. has completed its acquisition of Cullgen Inc. on May 4, 2026, through an Agreement and Plan of Merger and Reorganization.
• The transaction was an all-stock deal valued at approximately $300 million, with Cullgen becoming a wholly owned subsidiary of Gyre.
• The merger is intended to qualify as a tax-free reorganization.
• Following the merger, Ying Luo, Ph.D., former CEO of Cullgen, has been appointed CEO and President of Gyre and joined its Board of Directors.
• Ping Zhang will continue as Chairman of the Board.
• The combined company will operate as a U.S.- and China-based integrated biopharmaceutical company with a focus on fibrosis and inflammatory diseases.
• The acquisition includes Cullgen's targeted protein degrader (TPD) and degrader antibody conjugate (DAC) technologies.
• Gyre's existing commercial asset, ETUARY (pirfenidone capsule) for lung fibrosis in China, and its pipeline, including F351 for chronic hepatitis B-induced liver fibrosis, are now part of the combined entity.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development due to the strategic acquisition and pipeline expansion, though the all-stock nature and integration risks temper the score.

Positives

• Creation of a U.S.- and China-based fully integrated biopharmaceutical company.
• Combined entity possesses a revenue-producing commercial asset (ETUARY in China) and a robust pipeline.
• Acquisition of Cullgen's targeted protein degrader (TPD) and degrader antibody conjugate (DAC) technologies, strengthening the innovation engine.
• Strengthened leadership team with the appointment of Ying Luo as CEO and President.
• Focus on therapeutic areas of fibrosis and inflammatory diseases, with potential for global growth.
• F351 (hydronidone) has received priority review status from China's NMPA for its NDA and is being explored for ex-China development.
• ETUARY is undergoing Phase 3 trials for pneumoconiosis and a new indication (radiation-induced lung injury).
• The transaction is structured as an all-stock deal, potentially preserving cash for operations.

Negatives

• The integration of two companies presents inherent challenges and risks.
• The success of the combined entity relies on the successful development and commercialization of a complex pipeline, including novel TPD and DAC therapies.
• The company will need to manage operations across two distinct regulatory and market environments (U.S. and China).
• The all-stock nature of the deal dilutes existing Gyre shareholders.
• The filing does not provide specific financial metrics for Cullgen prior to the acquisition, making a direct comparison difficult.

Risks

• New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties.
• The company may not achieve the forecasts disclosed in its forward-looking statements.
• Risks associated with the clinical development and regulatory approval of product candidates, including potential delays.
• Uncertainties in obtaining successful clinical results and unexpected costs.
• Failure to realize any value from product candidates and preclinical programs.
• Potential adverse reactions or changes to business relationships resulting from the announcement or completion of the acquisition.
• The risk that the combined company may not be able to successfully integrate the businesses and realize the expected benefits of the acquisition in a timely manner or at all.
• The company may not be able to obtain sufficient additional capital to continue to advance its product candidates and preclinical programs.

Future Outlook

The company anticipates moving forward as a U.S.- and China-based fully integrated biopharmaceutical company with a full-spectrum pipeline focused on fibrosis and inflammatory diseases. This includes advancing F351 for ex-China territories, further developing ETUARY in new indications, and leveraging Cullgen's TPD and DAC technologies for long-term value.

Management Comments

• "We are eager to move forward as a U.S.- and China-based fully integrated biopharmaceutical company. Through this combination, we have created an entity that not only offers a commercial-stage product with ETUARY, on the market in China for the treatment of lung fibrosis, but also a full-spectrum pipeline of products from discovery to Phase 3, primarily focused on fibrosis and inflammatory diseases."
• "This combination occurs at an exciting time for Gyre as we recently received priority review status from the Center for Drug Evaluation of Chinas National Medical Products Administration for the F351 NDA in March. We are also exploring the expansion of F351s development in ex-China territories including the U.S."
• "In addition, we have completed enrollment in our 52-week Phase 3 ETUARY trial for pneumoconiosis, and have also enrolled the first patient in a Phase 3 study evaluating ETUARY in a new indication: radiation-induced lung injury with or without immune checkpoint inhibitor-related pneumonitis, further strengthening our late-stage inflammatory portfolio."
• "Additionally, we believe the innovative discovery engine that has produced several promising degraders and DACs acquired from Cullgen strengthens our asset portfolio and provides long-term value to Gyre."

Industry Context

StockSavvy.ai notes that this acquisition aligns with the trend of biopharmaceutical companies seeking to expand their global reach and pipeline diversity, particularly by integrating U.S. and China operations. The focus on targeted protein degraders and degrader-antibody conjugates reflects the industry's push towards novel therapeutic modalities for complex diseases like fibrosis and inflammatory conditions.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Existing Gyre shareholders will experience dilution due to the all-stock transaction. They will also benefit from the expanded pipeline and potential for future growth.
• Employees: Cullgen employees will become employees of Gyre, with their stock options and RSUs converted. Gyre employees may see changes in roles and responsibilities as the companies integrate.
• Management: New leadership roles have been established, with Ying Luo taking over as CEO and President, and Thomas Eastling appointed CFO.

Next Steps

• The company will hold a stockholders meeting on June 10, 2026, to vote on the conversion of Company Preferred Stock into Company Common Stock.
• Gyre will file a resale registration statement pursuant to the Registration Rights Agreement.
• Financial statements of Cullgen and pro forma financial information will be filed in an amendment to this Current Report on Form 8-K.

Key Dates

Recommendation

The acquisition creates a more diversified biopharmaceutical company with a commercial asset and a promising pipeline, including novel modalities. However, the success of the integration and the clinical/commercial execution of the combined entity's assets remain significant factors. The all-stock nature of the deal also introduces dilution. Therefore, a 'hold' recommendation is appropriate pending further clarity on integration progress and pipeline milestones.

Keywords

Gyre Therapeutics, Cullgen Inc., Acquisition, Merger, Biopharmaceutical, Targeted Protein Degrader, Deagder Antibody Conjugate, Fibrosis